Jaen Juan C. 4

What Happened
Juan C. Jaen, President of Arcus Biosciences (RCUS), was awarded a total of 157,000 shares on January 23, 2026 via two Form 4 entries: 31,000 shares reported as acquired at $0.00 and 126,000 shares reported as a derivative acquisition at $0.00. The $0.00 price indicates these were awards/grants (RSUs), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-23; Filing date/accession: 2026-01-26 (filed within the usual Form 4 reporting window).
• Reported amounts: 31,000 shares (direct award) + 126,000 derivative shares = 157,000 total.
• Reported price: $0.00 (award/grant), total consideration $0 in cash.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes:
  • F1: The RSU grant vests in four equal annual installments beginning December 15, 2026, subject to continued service.
  • F2: The derivative line includes the unvested portion of the Reporting Person's RSU grants.
  • F3: Describes an option vesting schedule (48 equal monthly installments after Jan 1, 2026); included in the filing notes but not a separate option exercise reported here.

Context
These entries reflect equity compensation (RSUs) awarded to the president and are typical for executive pay — mostly unvested and tied to continued employment, so they do not represent an immediate cash purchase or sale. Awards are informative about compensation and potential future dilution but do not by themselves signal the insider buying or selling stock in the open market.